Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study

详细信息    查看全文

• 作者：Shintaro Hirata (1)
  Kazuyoshi Saito (1)
  Satoshi Kubo (1)
  Shunsuke Fukuyo (1)
  Yasushi Mizuno (1)
  Shigeru Iwata (1)
  Masao Nawata (1)
  Norifumi Sawamukai (1)
  Kazuhisa Nakano (1)
  Kunihiro Yamaoka (1)
  Yoshiya Tanaka (1)
  
• 刊名：Arthritis Research & Therapy
• 出版年：2013
• 出版时间：October 2013
• 年：2013
• 卷：15
• 期：5
• 全文大小：
• 作者单位：Shintaro Hirata (1)
  Kazuyoshi Saito (1)
  Satoshi Kubo (1)
  Shunsuke Fukuyo (1)
  Yasushi Mizuno (1)
  Shigeru Iwata (1)
  Masao Nawata (1)
  Norifumi Sawamukai (1)
  Kazuhisa Nakano (1)
  Kunihiro Yamaoka (1)
  Yoshiya Tanaka (1)
  
  1. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi, Kitakyushu, 807-8555, Japan
  
• ISSN：1478-6354

文摘

Introduction Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to investigate whether disease activity score 28 (DAS28)- erythrocyte sedimentation rate (ESR) remission was preserved after discontinuation of ADA in patients with RA. Methods This is an observational but not a randomized controlled study. Among 197 RA patients who initiated with combination of ADA with concomitant MTX, 69 (35%) acquired DAS28 (ESR) < 2.6 for at least 24 weeks. Of those 69 patients, 51 went on ADA discontinuation with their consent, and finally 50 of those with follow-up of > 24 weeks were evaluated. The effect of discontinuing ADA on clinical disease activity, functional disability and radiographic progression were evaluated by DAS28 (ESR), the clinical disease activity index (CDAI) and the simplified disease activity index (SDAI), by a health assessment questionnaire-disability index (HAQ-DI) and by the modified total Sharp score (mTSS), respectively. Results The mean age of the participants was 59.5 years with the mean disease duration of 7.1 years. Out of the 50 patients, 29 (58%) were maintained in DAS28 (ESR) < 2.6 at 24 weeks after discontinuing ADA. A logistic regression analysis showed that DAS28 (ESR) at baseline significantly predicted a DAS28 (ESR) < 2.6 maintained after discontinuation of ADA, and a receiver-operating characteristic (ROC) analysis showed that the cut-off value of DAS28 (ESR) at discontinuation was 2.16. The mean HAQ-DI at six months after discontinuing ADA was 0.1 in patients who kept in DAS28 (ESR) < 2.6, and 94.9% (37/39) showed no evidence of radiographic progression (> 0.5 per year of a change in mTSS) at 1 year. Conclusions It was possible to maintain DAS28 (ESR) < 2.6 after discontinuation of ADA without functional and radiographic progression and very low DAS28 (ESR) at the discontinuation was associated with successful ADA-free DAS28 (ESR) < 2.6 in patients with RA. Trial registration University Hospital Medical Information Network Identifier: UMIN000006669.